- Home
- NEXN vs AVIR Comparison
NEXN vs AVIR Comparison
Compare NEXN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | AVIR |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | Israel | United States |
| Employees | 909 | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 434.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEXN | AVIR |
|---|---|---|
| Price | $9.55 | $4.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $11.56 | $10.00 |
| AVG Volume (30 Days) | 313.1K | ★ 316.0K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.60 | $2.78 |
| 52 Week High | $11.59 | $6.45 |
Technical Indicators
Market Signals| Indicator | NEXN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 64.90 |
| Support Level | $8.08 | $4.14 |
| Resistance Level | N/A | $6.37 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 88.67 | 93.21 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from America.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.